Coya Therapeutics, Inc. COYA
Set alert
3.61 USD -0.37 -9.30%
At close · Oct 30
3.68 +0.07 +1.94%
After hours · Oct 30, 4:00 PM ET
3.59 Day range 4.09
3.59 52-week range 6.62
- YTD
- -37.76%
- 1 year
- -41.01%
- Open
- 3.96
- Prev close
- 3.98
- Mkt cap
- 84.68M
- Vol
- 214.74K
- Avg vol
- 130.78K
- EPS
- -1.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.59
- High
- 4.09
- Forward P/E
- -4.25
- Beta
- 0.00
- Short ratio
- 1.53
- Inst. own
- 19.97%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 6.94
- 200-d avg
- 7.28
- 1y target
- 15.50
News
-
4 days ago benzinga.com
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment
ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes…
-
2 weeks ago benzinga.com
Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis
OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash…
-
3 weeks ago benzinga.com
Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis
120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible participants already in active screening will be allowed to enrollTopline data from 24-week…